Pacira Biosciences, Inc. revenue
Pacira Biosciences, Inc.'s revenue was $726m in fiscal 2025, up 3.6% on the year before. Since fiscal 2009 ($15.0m) it has grown at a compound 27.4% a year. Over the last twelve months it was $746m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 15 | 16 | 39 | 86 | 198 | 249 | 276 | 287 | 337 | 421 | 430 | 542 | 667 | 675 | 701 | 726 | 746 |
| Growth on the year before | — | −3.0% | +7.7% | +149.1% | +118.9% | +131.1% | +26.0% | +11.0% | +3.7% | +17.7% | +24.8% | +2.0% | +26.0% | +23.1% | +1.2% | +3.9% | +3.6% | — |
| Gross profit | 3 | 2 | −1 | 7 | 31 | 120 | 177 | 166 | 199 | 250 | 314 | 312 | 401 | 468 | 490 | 531 | 577 | 591 |
| Gross margin | 18.0% | 15.7% | −6.7% | 17.8% | 36.0% | 60.8% | 71.1% | 60.2% | 69.3% | 74.3% | 74.7% | 72.7% | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% | 79.2% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $723M | 99.1% | ▲ 3.7% |
| EXPAREL (part of Products) | $575M | 79.6% | ▲ 4.8% |
| ZILRETTA (part of Products) | $117M | 16.1% | ▼ 1.2% |
| Iovera (part of Products) | $24.2M | 3.3% | ▲ 6.0% |
| Royalty (part of Products) | $3.6M | 0.5% | ▼ 5.9% |
| Bupivacaine Liposome Injectable Suspension | $6.9M | 0.9% | ▼ 5.6% |
From Pacira Biosciences, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Pacira Biosciences, Inc. | $746m | 5.7% | 3.7% |
| Amphastar Pharmaceuticals, Inc. | $730m | 1.0% | 10.5% |
| Corcept Therapeutics Inc | $831m | 16.0% | 24.7% |
| Travere Therapeutics, Inc. | $651m | 49.4% | 71.3% |
| Emergent Biosolutions Inc. | $649m | -17.7% | -16.2% |
| Supernus Pharmaceuticals, Inc. | $865m | 26.9% | 12.3% |
Compare with peers
- Amphastar Pharmaceuticals, Inc. revenue
- Corcept Therapeutics Inc revenue
- Travere Therapeutics, Inc. revenue
- Emergent Biosolutions Inc. revenue
- Supernus Pharmaceuticals, Inc. revenue
Head to head: AMPH vs PCRXCORT vs PCRXPCRX vs TVTX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies